Publications by authors named "Abderrahim Fandi"

Claim this Profile
B
Beyond conventional adoptive T-cell therapy.
Marina Cavazzana, Juliette Paillet, Abderrahim Fandi, Ranjita Devi Moirangthem, Pierre Heimendinger

J Allergy Clin Immunol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Benjamin P Levy, Giuseppe Giaccone, Benjamin Besse, Enriqueta Felip, Marina Chiara Garassino, Abderrahim Fandi

Eur J Cancer· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis.
Javier Cortes, José Pérez-García, Scott Whiting, Yin Wan, Caitlyn Solem, Abderrahim Fandi

Clin Breast Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Nicholas J Vogelzang, Karim Fizazi, John M Burke, Ronald De Wit, Joaquim Bellmunt, Abderrahim Fandi

Eur Urol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
Ellen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, Nikolay Budnik, Pawel J Wiechno, Abderrahim Fandi

JAMA Oncol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
Guru Sonpavde, Gregory R Pond, Arnoud J Templeton, Abderrahim Fandi, Bertrand Tombal

Eur Urol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
Susan Halabi, William Kevin Kelly, Hua Ma, Haojin Zhou, Nicole C Solomon, Abderrahim Fandi

J Clin Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Daniel P Petrylak, Nicholas J Vogelzang, Nikolay Budnik, Pawel Jan Wiechno, Cora N Sternberg, Abderrahim Fandi

Lancet Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
Peter M Ellis, Ulf Jungnelius, Jennie Zhang, Abderrahim Fandi, Robert Beck

J Thorac Oncol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Primo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, Joachim von Pawel, Mark J McKeage, Abderrahim Fandi

J Clin Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Giuseppe Giaccone, Renee B Iacona, Abderrahim Fandi, Mette Janas, Judith S Ochs

J Cancer Res Clin Oncol· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming kinase resistance in chronic myeloid leukemia.
Francis Lee, Abderrahim Fandi, Maurizio Voi

Int J Biochem Cell Biol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines.
Fabio Timeus, Nicoletta Crescenzio, Abderrahim Fandi, Alessandra Doria, Luiselda Foglia

Oncol Rep· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients.
Jean-Louis Pujol, Patrick Viens, Paul Rebattu, Scott A Laurie, Ronald Feld, Abderrahim Fandi

J Thorac Oncol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Christian Manegold, Ulrich Gatzemeier, Erika Buchholz, Robert P Smith, Abderrahim Fandi

Clin Lung Cancer· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giuseppe Giaccone, Roy S Herbst, Christian Manegold, Giorgio Scagliotti, Rafael Rosell, Abderrahim Fandi

J Clin Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Roy S Herbst, Giuseppe Giaccone, Joan H Schiller, Ronald B Natale, Vincent Miller, Abderrahim Fandi

J Clin Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis